| Literature DB >> 29382075 |
Wenqing Cai1,2, Jingwei Wu3, Wei Liu4, Yafei Xie5, Yuqiang Liu6, Shuo Zhang7, Weiren Xu8, Lida Tang9, Jianwu Wang10, Guilong Zhao11.
Abstract
In order to systematically explore and better understand the structure-activity relationship (SAR) of a diarylmethane backbone in the design of potent uric acid transporter 1 (URAT1) inhibitors, 33 compounds (1a-1x and 1ha-1hi) were designed and synthesized, and their in vitro URAT1 inhibitory activities (IC50) were determined. The three-round systematic SAR exploration led to the discovery of a highly potent novel URAT1 inhibitor, 1h, which was 200- and 8-fold more potent than parent lesinurad and benzbromarone, respectively (IC50 = 0.035 μM against human URAT1 for 1h vs. 7.18 μM and 0.28 μM for lesinurad and benzbromarone, respectively). Compound 1h is the most potent URAT1 inhibitor discovered in our laboratories so far and also comparable to the most potent ones currently under development in clinical trials. The present study demonstrates that the diarylmethane backbone represents a very promising molecular scaffold for the design of potent URAT1 inhibitors.Entities:
Keywords: URAT1 inhibitor; gout; hyperuricemia; lesinurad; structure-activity relationship (SAR); synthesis
Mesh:
Substances:
Year: 2018 PMID: 29382075 PMCID: PMC6017028 DOI: 10.3390/molecules23020252
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411